News & Updates
Filter by Specialty:
Chronic hepatitis C tied to cardiovascular events in T2DM
In patients with type 2 diabetes mellitus (T2DM), chronic hepatitis C and fatty liver appear to worsen the risk of cardiovascular events, a recent Taiwan study has found.
Chronic hepatitis C tied to cardiovascular events in T2DM
19 Jul 2022
Resmetirom demos potential in NASH
Safety analysis of the phase III MAESTRO-NAFLD-1 trial presented at ILC 2022 demonstrated the potential of resmetirom as a treatment for patients with non-alcoholic steatohepatitis (NASH) who have liver fibrosis.
Resmetirom demos potential in NASH
18 Jul 2022
PARG inhibition slows HCC progression, boosts efficacy of immune checkpoint therapy
In hepatocellular carcinoma (HCC), poly(ADP-ribose) glycohydrolase (PARG) may serve as an oncogene by modulating PARG/DDB1/c-Myc signaling and be used as a biomarker to identify HCC patients who may derive benefit from anti-PD-1 treatment, suggests a study.
PARG inhibition slows HCC progression, boosts efficacy of immune checkpoint therapy
05 Jul 2022
Five-test universal HBV screening strategy most cost-effective in China
A nationally representative study led by researchers from the University of Hong Kong and Xi’an Jiaotong University Health Science Centre, China, has shown that a five-test (ie, serum HBsAg/HBsAb/HBeAg/HBeAb/HBcAb) universal screening strategy in people aged 18–70 years is the most cost-effective hepatitis B virus (HBV) screening option in China.
Five-test universal HBV screening strategy most cost-effective in China
28 Jun 2022
NAFLD linked to heightened type 2 diabetes risk
Children with nonalcoholic fatty liver disease (NAFLD) are at an increased risk of type 2 diabetes, a study reports. Other risk factors for T2D include severity of liver histology, body mass index, and female sex.